Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
|
CN |
|
T
|
TMC Life Sciences Bhd
KLSE:TMCLIFE
|
MY |
|
IPS Securex Holdings Ltd
SGX:42N
|
SG |
|
E
|
Etga Group Ltd
TASE:ETGA
|
IL |
|
Holtek Semiconductor Inc
TWSE:6202
|
TW |
|
K
|
Kitakei Co Ltd
TSE:9872
|
JP |
|
GMO Pepabo Inc
TSE:3633
|
JP |
|
TBS Energi Utama Tbk PT
IDX:TOBA
|
ID |
Wall Street
Price Targets
Price Targets Summary
Tonghua Dongbao Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Tonghua Dongbao Pharmaceutical Co Ltd is 11.19 CNY with a low forecast of 8.08 CNY and a high forecast of 14.7 CNY.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Tonghua Dongbao Pharmaceutical Co Ltd's stock price target?
Price Target
11.19
CNY
According to Wall Street analysts, the average 1-year price target for Tonghua Dongbao Pharmaceutical Co Ltd is 11.19 CNY with a low forecast of 8.08 CNY and a high forecast of 14.7 CNY.
What is Tonghua Dongbao Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
22%
For the last 13 years the compound annual growth rate for Tonghua Dongbao Pharmaceutical Co Ltd's revenue is 8%. The projected CAGR for the next 3 years is 22%.
What is Tonghua Dongbao Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
104%
For the last 13 years the compound annual growth rate for Tonghua Dongbao Pharmaceutical Co Ltd's operating income is 11%. The projected CAGR for the next 3 years is 104%.
